| Michael Isaac Hackman, MD | |
|
1600 Haddon Ave Fl 6, Camden, NJ 08103-3101 | |
| (856) 757-3500 | |
| (856) 365-4088 |
| Full Name | Michael Isaac Hackman |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 15 Years |
| Location | 1600 Haddon Ave Fl 6, Camden, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033353990 | NPI | - | NPPES |
| 0532681 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | A131092 (California) | Secondary |
| 208M00000X | Hospitalist | 25MA09938400 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Virtua Our Lady Of Lourdes Hospital | Camden, NJ | Hospital |
| Virtua West Jersey Hospitals | Voorhees, NJ | Hospital |
| Virtua Memorial Hospital Of Burlington County | Mount holly, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Virtua Medical Group, Pa | 9830222397 | 1226 |
News Archive
SP Industries (‘SP') has announced that Brian Wright has joined the company as Chief Operating Officer effective October 27, 2014.
A research team led by Dr. Kim Innes, a professor in the West Virginia University School of Public Health, has found that a simple meditation or music listening program may alter certain biomarkers of cellular aging and Alzheimer's Disease in older adults who are experiencing memory loss.
DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.
GfK will deliver a major presentation about patient perspectives' on personalized medicine at the Pharmaceutical Business and Intelligence Research Group Annual General Meeting, taking place May 19 to 22 in Naples, Florida.
When attacking body cells, bacteria, such as salmonellae or Yersinia (plague pathogens), inject specific bacterial proteins through hollow, syringe-like structures - called injectisomes - into the host cells. These substances reprogram the cells and can thus overcome their defense. From then on, they can infiltrate the cells unhindered in large numbers, and trigger diseases such as typhus, plague, or cholera.
› Verified 9 days ago
| Entity Name | Virtua Medical Group, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649226515 PECOS PAC ID: 9830222397 Enrollment ID: O20100804000338 |
News Archive
SP Industries (‘SP') has announced that Brian Wright has joined the company as Chief Operating Officer effective October 27, 2014.
A research team led by Dr. Kim Innes, a professor in the West Virginia University School of Public Health, has found that a simple meditation or music listening program may alter certain biomarkers of cellular aging and Alzheimer's Disease in older adults who are experiencing memory loss.
DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.
GfK will deliver a major presentation about patient perspectives' on personalized medicine at the Pharmaceutical Business and Intelligence Research Group Annual General Meeting, taking place May 19 to 22 in Naples, Florida.
When attacking body cells, bacteria, such as salmonellae or Yersinia (plague pathogens), inject specific bacterial proteins through hollow, syringe-like structures - called injectisomes - into the host cells. These substances reprogram the cells and can thus overcome their defense. From then on, they can infiltrate the cells unhindered in large numbers, and trigger diseases such as typhus, plague, or cholera.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Isaac Hackman, MD 301 Lippincott Dr Ste 410, Marlton, NJ 08053-4197 Ph: (856) 355-0340 | Michael Isaac Hackman, MD 1600 Haddon Ave Fl 6, Camden, NJ 08103-3101 Ph: (856) 757-3500 |
News Archive
SP Industries (‘SP') has announced that Brian Wright has joined the company as Chief Operating Officer effective October 27, 2014.
A research team led by Dr. Kim Innes, a professor in the West Virginia University School of Public Health, has found that a simple meditation or music listening program may alter certain biomarkers of cellular aging and Alzheimer's Disease in older adults who are experiencing memory loss.
DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.
GfK will deliver a major presentation about patient perspectives' on personalized medicine at the Pharmaceutical Business and Intelligence Research Group Annual General Meeting, taking place May 19 to 22 in Naples, Florida.
When attacking body cells, bacteria, such as salmonellae or Yersinia (plague pathogens), inject specific bacterial proteins through hollow, syringe-like structures - called injectisomes - into the host cells. These substances reprogram the cells and can thus overcome their defense. From then on, they can infiltrate the cells unhindered in large numbers, and trigger diseases such as typhus, plague, or cholera.
› Verified 9 days ago
Dr. Afaf A. Anter, D.O Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Dorrance 222, Camden, NJ 08103 Phone: 856-342-3150 Fax: 856-968-8418 | |
Dr. James Jingren Liu, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2000 | |
Kalpana Thawani, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1600 Haddon Ave, Camden, NJ 08103 Phone: 856-757-3700 Fax: 856-668-8479 | |
Pratik S Shah, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2000 | |
Dr. Gregory Hilditch, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2000 | |
Okebugwu Kamalu, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2000 | |
Maher Al-safadi, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2000 Fax: 856-968-8418 |